Aquestive Therapeutics, Inc. — Director's Dealing 2018

Jul 26, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aquestive Therapeutics, Inc. (AQST)
CIK: 0001398733
Period of Report: 2018-07-24

Reporting Person: BRATTON DOUGLAS K (Director, 10% Owner)
Reporting Person: Monoline Partners, L.P. (10% Owner)
Reporting Person: Bratton Capital Management, L.P. (10% Owner)
Reporting Person: Bratton Capital Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-24	Common Stock	P	165000	$15.00	Acquired	165000	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	75085	Direct
Common Stock	2249077	Indirect
Common Stock	2213314	Indirect
Common Stock	4032907	Indirect
Common Stock	2755541	Indirect
Common Stock	87455	Indirect

Footnotes

F1: These securities are beneficially owned by MonoLine Partners, L.P. ("MonoLine").

F2: These securities are owned, as indicated, by MonoLine, MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities". Bratton Capital Management, L.P. ("Bratton Capital Management") is the general partner of each of the Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director of Bratton and has voting and investment power over all shares held by the Monoline Entities.

F3: These securities are beneficially owned by MRX Partners.

F4: These securities are beneficially owned by Monoline Rx.

F5: These securities are beneficially owned by Monoline II.

F6: These securities are beneficially owned by Monoline III.

F7: These securities are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. The Reporting Person, Douglas K. Bratton, is the sole director of Bratton and has voting and investment power over all shares held by Monosol.

F8: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.